The relevance of our data to pancreatic cancer was reflected by the significant association between a high SOX2 protein level with an increased risk of tumor relapse and a poor survival of pancreatic cancer patients who underwent gemcitabine-based chemotherapy. This evidence concerns the gene SOX2 and pancreatic neoplasm.